Risk of new primaries after chemotherapy and/or tamoxifen treatment for early breast cancer

Annals of Oncology

Volumn 7, Issue 3, 1996, Pages 239-244

  Rubagotti, A ^a   Perrotta, A ^b   Casella, C ^b   Boccardo, F ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Adjuvant chemo tamoxifen therapy; Adjuvant chemotherapy; Adjuvant tamoxifen; Early breast cancer; Second malignancies

Indexed keywords

AMINOGLUTETHIMIDE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; MITOMYCIN C; TAMOXIFEN; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; EARLY CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SECOND CANCER;

EID: 0029926771     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010566     Document Type: Article

References (29)

1. Habs M, Schmal D, Linz PZ. Carcinogenic activity in rats of combined treatment with cyclophosphamide, methotrexate and 5-fluorouracil. Eur J Cancer 1981; 28: 91-6.
2. Weisburger EK. Bioassay program for carcinogenic hazards of cancer chemotherapeutic agents. Cancer 1977; 40: 1935-49.
3. Gottardis MM, Robinson SP, Satyaswaroop PG et al. Contrasting action of tamoxifen on endometrial and breast tumor growth in athymic mouse. Cancer Res 1988; 48: 812-5.
4. Greaves P, Goonetillebe R, Nunn G et al. Two-year carcinogenicity study of tamoxifen in Adderly Park Winstar-derived rats Cancer Res 1993; 53: 3919-24.
5. Fisher B, Rockette H, Fisher RR et al. Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative radiation: The NSABP experience. J Clin Oncol 1985; 3: 1640-58.
6. Herring MK, Buzdar AU, Smith TL et al. Second neoplasms after adjuvant chemotherapy for operable breast cancer. Am J Clin Oncol 1986; 9: 269-75.
7. Valagussa P, Moliterni A, Terenziani M et al. Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer. Ann Oncol 1994; 5: 803-8.
8. Lavey RS, Eby NL, Prosnitz LR. Impact of radiation therapy and/or chemotherapy on the risk for a second malignancy after breast cancer. Cancer 1990; 66: 874-81.
9. Arriagada R, Rutqvist LE. Adjuvant chemotherapy in early breast cancer and incidence of new primary malignancies. Lancet 1991; 338: 535-8.
10. Fornander T, Rutqvist LE, Cedemark B et al. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 1989; 1: 117-20.
11. Anderson M, Storm HH, Mouridsen HT. Incidence of new primary cancer after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 1991; 83: 1013-7.
12. Fisher B, Costantino JP, Redmond CK et al. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86: 527-37.
13. Boccardo F, Rubagotti A, Bruzzi P et al. Chemotherapy versus tamoxifen venus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: Results of a multicentric Italian study. J Clin Oncol 1990; 8: 1310-20.
14. Boccardo F, Rubagotti A, Amoroso D et al. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen receptor-positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-hormone Therapy Group) Trial. Eur J Cancer 1992; 28: 673-80.
15. Boccardo F, Amoroso D, Rubagotti A et al. Prolonged tamoxifen treatment of early breast cancer: The experience of the Italian Cooperative Group for Chemohormonal Therapy of Early Breast Cancer (GROCTA). In Craig Jordan V (ed): Long-term Tamoxifen Treatment for Breast Cancer. Madison, WI: The University of Wisconsin Press 1994; 159-79.
16. Kaplan EL, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-81.
17. Gelman R, Gelber R, Henderson IC et al. Improved methodology for analyzing local and distant recurrence. J Clin Oncol 1990; 8: 548-55.
18. Kramar A, Pejovic MH, Chassagne D. A method of analysis taking into account competing events: Application to the study of digestive complications following irradiation for cervical cancer. Stat Med 1987; 6: 785-94.
19. Lee ET. Statistical Methods for Survival Data Analysis. Belmont, CA: Like Time Learning Publications 1980.
20. Crosignani P, Gatta G, Sant M et al. Italy, Lombardy Region, Varese Province. In Parkin DM, Muir CS, Whelan SL et al. (eds): Cancer Incidence in Five Continents. Vol VI. IARC Scientific Publications no. 120, Lyon, France: International Agency for Research on Cancer 1992.
21. Breslow NE, Day NE. Statistical Methods in Cancer Research. Vol II. The Design and Analysis of Cohort Studies. IARC Scientific Publications no. 82, Lyon, France: International Agency for Research on Cancer 1987.
22. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339: 1-15, 71-85.
23. Jaiyesimi IA, Budzar AU, Decker DA et al. Use of tamoxifen for breast cancer: Twenty-eight years later. J Clin Oncol 1995; 13: 513-29.
24. Houghton J, Riley D, Baum M. The Nolvadex Adjuvant Trial Organisation (NATO) and the Cancer Research Campaign (CRC) Trials of adjuvant tamoxifen therapy. In Craig Jordan V (ed): Long-term Tamoxifen Treatment for Breast Cancer. Madison, WI: The University of Wisconsin Press 1994; 93-113.
25. Rutqvist LE, Johansson H, Signomklao T et al. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 1995; 87: 645-651.
26. Osborne CK, Kitten L, Arteaga CL. Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. J Clin Oncol 1989; 7: 710-7.
27. LeBlanc GA, Waxman DJ. Interaction of anticancer drugs with hepatic mono-oxygenase enzymes. Drug Metab Rev 1989; 20: 395-439.
28. 1 phase. Cancer Res 1983; 43: 3583-5.
29. Russo IH, Russo J. From pathogenesis to hormone prevention of mammary carcinogenesis. Cancer Surv 1986; 5: 649-70.